Appendix 3. Description of interventions (part 2).

Characteris- tic	Jing A, 2009	Li KL, 2006	Li LH, 2005	Liu L, 2000	Lu GP, 1998	Ma YL, 2002	Qi MY, 2004
Intervention (s) [route, frequency, to- tal dose/day]	I: DMC orally, 2 times a day, 4 g/day	I: Xuezhikang orally, 2 times a day, 1 g/day	I: Xuezhikang orally, 2 times a day, 1.2 g/day	I: Xuezhikang orally,2 times a day, 1.2 g/day	I: Xuezhikang orally, daily, 1.2 g/day	I: Xuezhikang orally, 3 times a day, 6 capsules/day	I: Xuezhikang orally, 2 times a day, 2.4 g/day
Control(s) [route, frequency, to- tal dose/day]	C: pravastatin orally, daily, 10 mg/day	C: simvastatin orally, daily, 10 mg/day	C1: pravastatin orally, daily, 10mg/day C2: simvastatin orally, daily, 20 mg/day	C: inositol nicotinate orally, 2 times a day, 0.8 g/day	C: simvastatin orally, 2 times a day, 20 mg/day	C: marine triglycerids orally, 3 times a day, 9 capsules/day	C: simvastatin orally, daily, 10 mg/day

Footnotes

C: control; I: intervention